Determination of loxapine in human plasma and urine and identification of three urinary metabolites.
1. A g.l.c. method for quantitative determination of loxapine (2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine), in human plasma and urine is described. 2. Preliminary pharmacokinetic data on plasma concn of loxapine over 12 h from five psychiatric patients who received a total average dose of 80 mg of loxapine succinate per day orally for twelve weeks are presented. 3. In addition to unchanged loxapine, three urinary metabolic products, namely aromatic ring-hydroxy loxapine, desmethyl loxapine and loxapine-N-oxide, were identified using g.l.c.--mass spectrometry.
D000328:Adult; D002849:Chromatography, Gas / Q000379:methods; D003989:Dibenzoxazepines / Q000097:blood* / Q000652:urine*; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006801:Humans; D007700:Kinetics; D008152:Loxapine / Q000031:analogs & derivatives / Q000097:blood* / Q000627:therapeutic use / Q000652:urine*; D008297:Male; D008875:Middle Aged; D008956:Models, Chemical; D011618:Psychotic Disorders / Q000188:drug therapy*
D003989:Dibenzoxazepines; D008152:Loxapine